Post-earnings recap
Reported
Thu, Feb 12, 2026
EPS actual
$-1.29
EPS est.
$-1.20
EPS surprise
-7.32%
1-day move
-1.59%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Ultragenyx Pharma's earnings report shows a miss on EPS, which contributed to a 1.59% decline in stock price. The company did not provide revenue figures or future guidance, leaving investors uncertain about its financial trajectory. Management's defensive tone suggests they are facing challenges but are focused on long-term strategies.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.29 | N/A | -7.32% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over recent performance but remains committed to their strategic initiatives. They did not provide specific guidance for the upcoming quarters.
Management acknowledged ongoing challenges in the market.
They emphasized a focus on long-term strategies despite current setbacks.